Ananda Pharma (AQSE: ANA), is a UK-based developer of licenced, CBD-based medicinal products, has appointed Andy Rust as a commercial adviser, to provide the company with expert advice on its drug development and commercialisation plans.
Rust’s most recent role was as Global Head of Respiratory with Chiesi Group, an international biopharmaceutical company which has a direct presence in 31 countries. At Chiesi, he led the strategic direction and execution of the group’s respiratory portfolio, which included products for asthma and COPD, to significantly grow revenues for the company’s respiratory range to in excess of €1.5 billion, Ananda said in its press release.
Ananda’s CEO, Melissa Sturgess said: “We are delighted to have Andy join us as a commercial adviser. In our determination to bring cannabinoid drugs to market, including two forthcoming NHS sponsored phase 3 clinical trials, we are ensuring we always have our focus on the prize, which means understanding the marketing and sales ramifications of all our decisions along the way.”